Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome

Blood

Volumn 91, Issue 8, 1998, Pages 3011-3016

  Nadali, Gianpaolo ^b   Tavecchia, Luisa ^b   Zanolin, Elisabetta ^b   Bonfante, Valeria ^b   Viviani, Simonetta ^b   Camerini, Edgarda ^b   Musto, Pellegrino ^b   Di Renzo, Nicola ^b   Carotenuto, Mario ^b   Chilosi, Marco ^b   Krampera, Mauro ^b   Pizzolo, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; HEMOGLOBIN;

ADULT; ARTICLE; CANCER SURVIVAL; FEMALE; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SYMPTOMATOLOGY;

EID: 0032523174     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.3011.3011_3011_3016     Document Type: Article

References (42)

1. Straus DJ: Treatment of Hodgkin's disease: The role of radio- and/or chemotherapy in advanced stages. Bailliere's Clin Haematol 9:553, 1997
2. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Paterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478, 1992
3. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced stage Hodgkin's disease: A preliminary report. J Clin Oncol 13:1080, 1995
4. Gause BL, Longo DL: Treatment of relapsed Hodgkin's disease. Bailliere's Clin Haematol 9:559, 1997
5. Horning J, Chao NJ, Negrin RS, Hoppe RT, Long GD, Wendy WH, Wong RM, Brown BW, Blume KJ: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 3:801, 1997
6. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaloy S, Host H: Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time and age. J Clin Oncol 11:255, 1993
7. Henry-Amar M: Treatment sequelae and quality of life. Bailliere's Clin Haematol 9:559, 1997
8. van Tulder MW, Aaronson NK, Bruning PF: The quality of life of long term survivors of Hodgkin's disease. Ann Oncol 5:153, 1994
9. Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J, Clarkson BD: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8:1173, 1990
10. Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbee KA, Monconduit M, de Pauw BE, Breed WPM, Verdonk L, Burgers JMV, Eghbali H, Zittoun R: A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 12:279, 1994
11. Colonna P, Jais JP, Desablens B, Harousseau JL, Brière J, Boasson M, Lemevel A, Casassus P, La Prisé PY, Guilhot F, Ghandour C, Lejeune F, Andrieu JM: Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 14:1928, 1996
12. Anderson H, Jenkins JPR, Brigg DJ: The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: A report from the Manchester Lymphoma Group. Clin Radiol 36:449, 1985
13. Hasenclever D, Diehl V: A numerical index to predict tumor control in advanced Hodgkin's disease. Blood 88:673a, 1996 (suppl 1, abstr)
14. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chilosi M, Menestrina F, Fiacchini M, Stein H, Pizzolo G: Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 12:793, 1994
15. Durkop H, Latza U, Hummel M: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421, 1992
16. Smith C, David T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RG: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019, 1990
17. Schwab U, Stein H, Gerdes J: Production of a monoclonal antibody specific for Hodgkin's and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299:65, 1982
18. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F: Hodgkin's disease: A tumor with disturbed immunological pathways. Immunol Today 18:156, 1997
19. Josimovic-Alasevic O, Dürkop H, Schwarting R, Backe E, Stein H, Diamantstein T: Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19:157, 1989
20. Dallenbach F, Josimovic-Alasevic O, Durkop H: Soluble CD30 antigen in the sera of patients with adult T-cell lymphoma/leukaemia (ATL): A marker for disease activity, in Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGKr (eds): Leucocyte Typing IV: White Cell Differentiation Antigens. Oxford, UK, Oxford University Press, 1989, p 426
21. Pizzolo G, Vinante F, Chilosi M, Dallenbach F, Josimovic-Alasevic O, Diamantstein T, Stein H: Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: Relationship with disease activity and clinical stage. Br J Haematol 75:282, 1990
22. Pizzolo G, Stein H, Josimovic-Alasevic O, Vinante F, Zanotti R, Chilosi M, Feller AC, Diamantstein T: Increased serum levels of soluble IL-2 receptor, CD30, and CD8 molecules, and gamma interferon in angioimmunoblastic lymphadenopathy. Possible pathogenetic role of immunoactivation mechanisms. Br J Haematol 75:485, 1990
23. Gause A, Pohl C, Tschiersch A, Da Costa L, Jung W, Diehl V, Hasenclever D, Pfreundschuh M: Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 77:1983, 1991
24. + lymphoma. Haematologica 80:357, 1995
25. Del Prete G, Maggi E, Pizzolo G, Romagnani S: CD30, Th2 cytokines and HIV infection: A complex and fascinating link. Immunol Today 16:76, 1995
26. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1, 1995
27. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
28. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630, 1989
29. Hoppe RT: Radiation therapy in the management of Hodgkin's disease. Semin Oncol 17:704, 1990
30. Longo DL: The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol 17:716, 1990
31. Gobbi PG, Pierasca C, Frassoldati A, Carotenuto M, Di Renzo N, La Sala A, Bertè R, Avanzini P, Federico M, Silingardi V, Ascari E: Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: The Gruppo Italiano per lo Studio dei Linfomi experience. J Clin Oncol 14:527, 1996
32. Bonfante V, Santoro A, Viviani S: ABVD plus radiotherapy (subtotal vs involved field) in early-stage Hodgkin's disease. Proc Am Soc Clin Oncol 13:1262a, 1994 (abstr)
33. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C: Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252, 1975
34. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 14:1421, 1996
35. Viviani S, Santoro A, Devizzi L: VEBEP plus involved-field RT: Efficacy and feasibility of an intensive regimen for advanced Hodgkin's disease (HD). Proc Am Soc Clin Oncol 14:1239a, 1995 (abstr)
36. Gobbi PG, Pierasca C, Federico M, Di Renzo N, Narni F, Iannitto E, Grignani G, Cavanna L, Avanzini P, Partesotti G, Pitini V, Ascari E, Silingardi V, Mauri C: MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: A report from the Italian Lymphoma Study Group. J Clin Oncol 11:712, 1993
37. Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandini G, Sinicco A, Raiteri R, Semenzato G, Stein H, Perona G: High serum level of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 8:741, 1994
38. Altman DG: Practical Statistics for Medical Research. London, UK, Chapman & Hall, 1992
39. Jaffe NS, Cadman EC, Farber LR: Pretreatment hematocrit as an independent prognostic variable in Hodgkin's disease. Blood 68:562, 1986
40. Proctor SJ, Taylor P, Donnan P, Boys R, Lennard A, Prescott RJ: A numerical index for clinical use in identification of poor-risk patients with Hodgkin's at diagnosis. Eur J Cancer 27:624, 1991
41. Specht L, Nissen NI, Walbom-Jorgensen S: Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. Scand J Haematol 35:166, 1985
42. International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993